Reputed research and clinical institutions from several countries were involved in the scientific agenda of the WCVII 2012, and their delegates assured a high scientific and medical standard for the Congress. It should be pointed out that the World Congress on Vaccines Immunisation and Immunotherapy, created in 1997 by ICWO, is the first original Congress of its kind, offering a unique forum for all specialists in immunisation and immunotherapy, research scientists developing new vaccines, industry leaders producing vaccines, and public health administrators in preventive medicine. The WCVII is contributing to the dissolution of isolation and barriers in the matters of global vaccinology, giving to all attendees from academia, industry and health institutions the unlimited possibility to express their views and share research data. This well reputed and original global Congress organized by scholars is the most recognized academic and independent medical research forum and is of very high standards. The WCVII has been and continues to set an example with regards to medical and scientific global strategic cooperation, with aim of reducing the suffering, misery, and enormous losses caused by infectious diseases and cancer. The WCVII is the longest running international forum for the latest developments in the field of vaccine, immunisation and immune therapy.
At the WCVII 2012, among important lectures, several discussions were devoted to children and adolescent immunisation. The value of implementation of HPV vaccination, of multi-antigen bacterial vaccines for prevention of meningococcal disease, staphylococcal and streptococcal infections was underlined. Progress in the elimination of measles and congenital rubella was reported, as well as on malaria vaccine models and clinical trials in Africa. Attention was given to evaluation of vaccine new adjuvants, to delivery technology of mucosal vaccines, to therapeutic vaccination, to novel monoclonal antibody immunotherapy and to amyloid-beta vaccine for treating Alzheimer's disease. Lectures and discussions on the progress in research on vaccines against cancer and emerging infections were appreciated. The development of ideal new generation of seasonal and pandemic influenza virus vaccines was reported by the delegate from the United States Department of Health and Human Services. In the U.S., the Government goal is to produce 300 million treatment courses of vaccination within six months of influenza pandemic outbreak. Interesting lectures were given on the progress in HIV/AIDS vaccines, on transcutaneous vaccination, on vectored and recombinant, multi-component vaccines against infectious diseases, and on plant-based system producing vaccines and specific biologics. Research investigators reported progress in anti-cancer and disease therapeutic vaccines with the discovery and development of antigens for immune therapy, including against tuberculosis. Attention was also focused on the economic value and benefits of vaccination and therapy.
This special issue of Human Vaccines & Immunotherapeutics, published by Landes Bioscience, contains 35 selected manuscripts divided into the following parts: (I) Towards new vaccines, immunisation strategies and immunotherapy; (II) Advances in epidemiological analysis and immunisation research; (III) Vaccines effectiveness, cost, economic benefits and risk factors.
Sincere thanks and appreciation go to the authors of manuscripts and to the staff of Human Vaccines & Immunotherapeutics for their cooperation in publishing this important volume. Our wish is that this special issue of Human Vaccines & Immunotherapeutics, as a source of latest information, be a useful tool for colleagues involved in the prevention and global control of infectious diseases and cancer at the levels of research and medical practice.
The 9th World Congress on Vaccines, Immunisation and Immunotherapy will be announced in due time. Academic and scientific values will continue to be well respected by the organisers. 
